Pharmaron Beijing Co (SZSE:300759) Total Liabilities : ¥11,887 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Total Liabilities?

Pharmaron Beijing Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥11,887 Mil.

Pharmaron Beijing Co's quarterly Total Liabilities increased from Sep. 2023 (¥9,749.33 Mil) to Dec. 2023 (¥13,238.67 Mil) but then declined from Dec. 2023 (¥13,238.67 Mil) to Mar. 2024 (¥11,886.96 Mil).

Pharmaron Beijing Co's annual Total Liabilities increased from Dec. 2021 (¥8,093.82 Mil) to Dec. 2022 (¥9,652.69 Mil) and increased from Dec. 2022 (¥9,652.69 Mil) to Dec. 2023 (¥13,238.67 Mil).

Pharmaron Beijing Co Total Liabilities Historical Data

The historical data trend for Pharmaron Beijing Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Total Liabilities Chart

Pharmaron Beijing Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2,097.02

2,975.05

8,093.82

9,652.69

13,238.67

Pharmaron Beijing Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															9,772.96	10,083.18	9,749.33	13,238.67	11,886.96

Pharmaron Beijing Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pharmaron Beijing Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3654.476	+	(8784.863	+	799.327
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	13,239

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	26476.713	-	13238.046
	=	13,239

Pharmaron Beijing Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3756.103	+	(7388.346	+	742.507
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	11,887

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	25243.967	-	13357.011
	=	11,887

Pharmaron Beijing Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaron Beijing Co (SZSE:300759) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (SZSE:300759) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

03759:Hong Kong 17Q1:Germany

Address

No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG

Website

https://www.pharmaron.com

Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.

Executives

Lou Xiao Qiang	Directors, executives
Zheng Bei	Directors, executives

Pharmaron Beijing Co (SZSE:300759) Headlines

No Headlines